1
|
Robitaille K, Guertin MH, Jamshidi A, Xu HW, Hovington H, Pelletier JF, Beaudoin L, Gevariya N, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Lodde M, Racine É, Trudel D, Perigny M, Duchesne T, Savard J, Julien P, Fradet Y, Fradet V. A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation. COMMUNICATIONS MEDICINE 2024; 4:56. [PMID: 38519581 PMCID: PMC10960033 DOI: 10.1038/s43856-024-00456-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Accepted: 02/07/2024] [Indexed: 03/25/2024] Open
Abstract
BACKGROUND High prostate eicosapentaenoic fatty acid (EPA) levels were associated with a significant reduction of upgrading to grade group (GG) ≥ 2 prostate cancer in men under active surveillance. We aimed to evaluate the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation. METHODS A phase II double-blind randomized placebo-controlled trial was conducted in 130 men diagnosed with GG ≥ 2 prostate cancer and undergoing radical prostatectomy between 2015-2017 (Clinicaltrials.gov: NCT02333435). Participants were randomized to receive 3 g daily of either MAG-EPA (n = 65) or placebo (n = 65) for 7 weeks (range 4-10) prior to radical prostatectomy. The primary outcome was the cancer proliferation index quantified by automated image analysis of tumor nuclear Ki-67 expression using standardized prostatectomy tissue microarrays. Additional planned outcomes at surgery are reported including plasma levels of 27 inflammatory cytokines and fatty acid profiles in circulating red blood cells membranes and prostate tissue. RESULTS Cancer proliferation index measured by Ki-67 expression was not statistically different between the intervention (3.10%) and placebo (2.85%) groups (p = 0.64). In the per protocol analyses, the adjusted estimated effect of MAG-EPA was greater but remained non-significant. Secondary outcome was the changes in plasma levels of 27 cytokines, of which only IL-7 was higher in MAG-EPA group compared to placebo (p = 0.026). Men randomized to MAG-EPA prior to surgery had four-fold higher EPA levels in prostate tissue compared to those on placebo. CONCLUSIONS This MAG-EPA intervention did not affect the primary outcome of prostate cancer proliferation according to nuclear Ki-67 expression. More studies are needed to decipher the effects of long-chain omega-3 fatty acid dietary supplementation in men with prostate cancer.
Collapse
Affiliation(s)
- Karine Robitaille
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada
- Institute of nutrition and functional foods (INAF) and NUTRISS Center - Nutrition, health and society of Université Laval, Québec, G1V 0A6, Canada
| | - Marie-Hélène Guertin
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada
| | - Afshin Jamshidi
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada
| | - Hui Wen Xu
- Department of Mathematics and Statistics, Université Laval, Québec, QC, G1V 0A6, Canada
| | - Hélène Hovington
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada
| | | | - Lisanne Beaudoin
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
| | - Nikunj Gevariya
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
| | - Louis Lacombe
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada
- Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada
| | - Rabi Tiguert
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada
| | - Yves Caumartin
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada
| | - Thierry Dujardin
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada
| | - Paul Toren
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada
- Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada
| | - Michele Lodde
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada
| | - Étienne Racine
- Department of Pathology, CHU de Québec-Université Laval, Québec, QC, G1R 2J6, Canada
| | - Dominique Trudel
- Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) et Institut du cancer de Montréal, and Department of Pathology and Cellular Biology, Université de Montréal, Montréal, H3C 3J7, Canada
| | - Martine Perigny
- Department of Pathology, CHU de Québec-Université Laval, Québec, QC, G1R 2J6, Canada
| | - Thierry Duchesne
- Department of Mathematics and Statistics, Université Laval, Québec, QC, G1V 0A6, Canada
| | - Josée Savard
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada
- School of psychology, Université Laval, Montréal, QC, G1R 2J6, Canada
| | - Pierre Julien
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada
| | - Yves Fradet
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada
- Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada
| | - Vincent Fradet
- CHU de Québec-Université Laval Research Center, Québec, QC, G1R 3S1, Canada.
- Centre de recherche sur le Cancer de l'Université Laval, Québec, QC, G1R 3S3, Canada.
- Institute of nutrition and functional foods (INAF) and NUTRISS Center - Nutrition, health and society of Université Laval, Québec, G1V 0A6, Canada.
- Centre de Recherche Clinique et Évaluative en Oncologie de L'Hôtel-Dieu de Québec, CHU de Québec-Université Laval, Québec, QC, G1R 3S1, Canada.
| |
Collapse
|
2
|
Maia R, Santos GAD, Reis S, Viana NI, Pimenta R, Guimarães VR, Recuero S, Romão P, Leite KRM, Srougi M, Passerotti CC. Can we use Ki67 expression to predict prostate cancer aggressiveness? Rev Col Bras Cir 2022; 49:e20223200. [PMID: 35792806 PMCID: PMC10578861 DOI: 10.1590/0100-6991e-20223200-en] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Accepted: 04/06/2022] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION specialists have an urge for biomarkers that can discriminate indolent prostate cancer from aggressive tumors. Ki67 is a proliferation marker, and its expression is associated with the aggressiveness of several cancers. OBJECTIVE analyze the expression of Ki67 in prostate cancer samples correlating with the aggressiveness of the disease. METHODS Ki67 mRNA levels were determined utilizing data from a TCGA cohort (Tumor(n)=492 and control(n)=52). The protein expression was determined on 94 biopsies from patients by immunohistochemical assay. RESULTS in mRNA, the Ki67 upregulation is associated with cancer tissue (p<0.0001) and worst disease-free survival (p=0.035). The protein upregulation is associated with increase of the ISUP score (p<0.0001), cancer stage (p=0.05), biochemical recurrence (p=0.0006) and metastasis (p<0.0001). We also show a positive correlation between Ki67 expression and ISUP score (r=0.5112, p<0.0001) and disease risk stratification (r=0.3388, p=0.0009). Ki67 expression is a factor independently associated with biochemical recurrence (p=0.002) and metastasis (p<0.0001). Finally, the patients with high Ki67expression shows better survival regarding biochemical recurrence (p=0.008) and metastasis (p=0.056). Patients with high Ki67 expression are 2.62 times more likely to develop biochemical recurrence (p=0.036). CONCLUSION Ki67 upregulation is associated with prostate cancer aggressiveness.
Collapse
Affiliation(s)
- Ronaldo Maia
- - Hospital Alemão Oswaldo Cruz, Center for Robotic Surgery - São Paulo - SP - Brasil
| | - Gabriel Arantes Dos Santos
- - Faculdade de Medicina da Universidade de São Paulo (FMUSP), Urologia - São Paulo - SP - Brasil
- - D'Or Institute for Research and Education (IDOR) - São Paulo - SP - Brasil
| | - Sabrina Reis
- - Faculdade de Medicina da Universidade de São Paulo (FMUSP), Urologia - São Paulo - SP - Brasil
- - Hospital Moriah - São Paulo - SP - Brasil
- - Universidade do Estado de Minas Gerais (UEMG) - Passos - MG - Brasil
| | - Nayara I Viana
- - Hospital Alemão Oswaldo Cruz, Center for Robotic Surgery - São Paulo - SP - Brasil
| | - Ruan Pimenta
- - Faculdade de Medicina da Universidade de São Paulo (FMUSP), Urologia - São Paulo - SP - Brasil
- - D'Or Institute for Research and Education (IDOR) - São Paulo - SP - Brasil
| | - Vanessa R Guimarães
- - Faculdade de Medicina da Universidade de São Paulo (FMUSP), Urologia - São Paulo - SP - Brasil
| | - Saulo Recuero
- - Faculdade de Medicina da Universidade de São Paulo (FMUSP), Urologia - São Paulo - SP - Brasil
| | - Poliana Romão
- - Faculdade de Medicina da Universidade de São Paulo (FMUSP), Urologia - São Paulo - SP - Brasil
| | | | - Miguel Srougi
- - Faculdade de Medicina da Universidade de São Paulo (FMUSP), Urologia - São Paulo - SP - Brasil
- - D'Or Institute for Research and Education (IDOR) - São Paulo - SP - Brasil
| | | |
Collapse
|
3
|
MAIA RONALDO, SANTOS GABRIELARANTESDOS, REIS SABRINA, VIANA NAYARAI, PIMENTA RUAN, GUIMARÃES VANESSAR, RECUERO SAULO, ROMÃO POLIANA, LEITE KATIARAMOSMOREIRA, SROUGI MIGUEL, PASSEROTTI CARLOCARMARGO. Podemos usar a expressão de Ki67 para prever a agressividade do câncer de próstata? Rev Col Bras Cir 2022. [DOI: 10.1590/0100-6991e-20223200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
RESUMO Introdução: especialistas precisam biomarcadores que podem discriminar o câncer de próstata indolente de tumores agressivos. Ki67 é um marcador de proliferação, e sua expressão está associada à agressividade de vários tumores. Objetivo: analisar a expressão do Ki67 em amostras de câncer de próstata correlacionando com a agressividade da doença. Métodos: os níveis de mRNA de Ki67 foram determinados utilizando dados de uma coorte de TCGA (Tumor(n)=492 e controle(n)=52). A expressão da proteína foi determinada em 94 biópsias de pacientes por ensaio imuno-histoquímica. Resultados: no mRNA, a superexpressão Ki67 está associada ao tecido canceroso (p<0,0001) e à pior sobrevida livre de doença (p=0,035). A superexpressão proteica está associada ao aumento do escore ISUP (p<0,0001), estágio de câncer (p=0,05), recorrência bioquímica (p=0,0006) e metástase (p<0,0001). Também mostramos uma correlação positiva entre a expressão Ki67 e o escore ISUP (r=0,5112, p<0,0001) e a estratificação de risco de doença (r=0,3388, p=0,0009). A expressão Ki67 é um fator independentemente associado à recorrência bioquímica (p=0,002) e metástase (p<0,0001). Finalmente, os pacientes com alta expressão de Ki67 expression mostram melhor sobrevivência em relação à recorrência bioquímica (p=0,008) e metástase (p=0,056). Os pacientes com alta expressão de Ki67 são 2,62 vezes mais propensos a desenvolver recorrência bioquímica (p=0,036). Conclusão: a superexpressão Ki67 está associada à agressividade do câncer de próstata.
Collapse
Affiliation(s)
| | | | - SABRINA REIS
- Universidade de São Paulo, Brazil; Hospital Moriah, Brasil; Universidade do Estado de Minas Gerais, Brazil
| | | | - RUAN PIMENTA
- Universidade de São Paulo, Brazil; D’Or Institute for Research and Education, Brasil
| | | | | | | | | | - MIGUEL SROUGI
- Universidade de São Paulo, Brazil; D’Or Institute for Research and Education, Brasil
| | | |
Collapse
|
4
|
Broggi G, Lo Giudice A, Di Mauro M, Pricoco E, Piombino E, Ferro M, Caltabiano R, Morgia G, Russo GI. Insulin signaling, androgen receptor and PSMA immunohistochemical analysis by semi-automated tissue microarray in prostate cancer with diabetes (DIAMOND study). Transl Res 2021; 238:25-35. [PMID: 34314871 DOI: 10.1016/j.trsl.2021.07.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 07/03/2021] [Accepted: 07/15/2021] [Indexed: 12/16/2022]
Abstract
In the last years, many studies have highlighted the hypothesis that diabetes and hyperglycemia could be relevant for prostate cancer (PC) development and progression. We aimed to identify the prognostic value of tissue expression of androgen receptor (AR), Prostate-Specific Membrane Antigen (PSMA), Ki-67, insulin receptors (IR) α and β, insulin growth factor-1 (IGF-1) receptor, in patients with PC and to evaluate their association with diabetes. We retrospectively collected data from 360 patients who underwent radical prostatectomy for PC or surgery for benign prostatic hyperplasia (BPH), between 2010 and 2020. We constructed tissue microarray for immunohistochemistry (IHC) analysis. In the final cohort (76 BPH and 284 PC), 57 (15.8%) patients had diabetes, 17 (22.37%) in BPH and 40 (14.08%) in PC (P = 0.08). IR-α was more expressed in patients with PC compared to the BPH Group (95.96% vs 4.04%; P <0.01). We found that AR was associated with increased risk of International Society of Urological Pathology (ISUP) score ≥4 (OR: 2.2; P <0.05), higher association with Ki-67 (OR: 2.2; P <0.05) and IR-α (OR: 5.7; P <0.05); IGF-1 receptor was associated with PSMA (OR: 2.8; P <0.05), Ki-67 (OR: 3.5; P <0.05) and IR-β (OR: 5.1; P <0.05). Finally, IGF-1 receptor was predictive of ISUP ≥ 4 (OR: 16.5; P =0.017) in patients with PC and diabetes. In the present study we highlighted how prostate cancer patients have a different protein expression in the tissue. This expression, and in particular that relating to IGF-1R, is associated with greater tumor aggressiveness in those patients with diabetes. We suppose that these results are attributable to an alteration of the insulin signal which therefore determines a greater mitogenic activity that can influence tumor progression.
Collapse
Affiliation(s)
- Giuseppe Broggi
- Department of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123, Catania, Italy
| | - Arturo Lo Giudice
- Department of Surgery, Urology Section, University of Catania, Catania, Italy; Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy
| | - Marina Di Mauro
- Department of Surgery, Urology Section, University of Catania, Catania, Italy
| | - Elisabetta Pricoco
- Department of Surgery, Urology Section, University of Catania, Catania, Italy
| | - Eliana Piombino
- Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), 95029, Catania, Italy
| | - Matteo Ferro
- Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy
| | - Rosario Caltabiano
- Department of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123, Catania, Italy
| | - Giuseppe Morgia
- Department of Surgery, Urology Section, University of Catania, Catania, Italy; Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), 95029, Catania, Italy
| | - Giorgio Ivan Russo
- Department of Surgery, Urology Section, University of Catania, Catania, Italy.
| |
Collapse
|
5
|
Broggi G, Lo Giudice A, Di Mauro M, Asmundo MG, Pricoco E, Piombino E, Caltabiano R, Morgia G, Russo GI. SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study). Prostate 2021; 81:882-892. [PMID: 34196424 PMCID: PMC8362056 DOI: 10.1002/pros.24185] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 05/25/2021] [Accepted: 06/07/2021] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To study the association between insulin receptors (isoforms α and β), insulin growth factor-1 (IGF1) and serine/arginine splicing factor 1 (SRSF-1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androgen receptor (AR), insulin receptor-α and -β, IGF1 (IGF1-R), Ki-67, and prostate specific membrane antigen (PSMA) expression using validated score. RESULTS The final cohort was represented by 100 patients with BPH and 268 with PC, with a median age of 68 years. We found that SRSF-1 expression was associated with AR (odds ratio [OR]: 1.66), PSMA (OR: 2.13), Ki-67 (OR: 5.99), insulin receptor (IR)-α (OR: 2.38), IR-β (OR: 3.48), IGF1-R (OR: 1.53), and microvascular density (MVD) was associated with PSMA (OR: 3.44), Ki-67 (OR: 2.23), IR-α (OR: 2.91), IR-β (OR: 3.02), IGF1-R (OR: 2.95), and SRSF-1 (OR: 2.21). In the sub cohort of PC patients, we found that SRSF-1 expression was associated with AR (OR: 2.34), Ki-67 (OR: 6.77), IR-α (OR: 2.7), and MVD (OR: 1.98). At the Kaplan-Meier analysis, SRSF-1+ patients had worse 5- and 9-year biochemical recurrence (36% and 6%) respect to SRSF-1- (67% and 7%; p < .01) and similarly MVD+ patients (44% and 7%) respect to MVD- (64% and 8%; p < .01). Restricting the analysis only in patients with PC and diabetes, we found that SRSF-1+ was associated with Ki-67+ (OR: 8.75; p < .05) and MVD+ (OR: 7.5; p < .05). CONCLUSIONS PC exhibits widespread heterogeneity in protein expression. In particular, the expressions of the SRSF-1 protein and of the MVD are associated with a worse prognosis and in particular with a greater cell proliferation. These results, although preliminary, may offer new future scientific insights with the aim of highlighting possible genetic alterations linked to a greater expression of SRSF-1 and associated with a worse prognosis.
Collapse
Affiliation(s)
- Giuseppe Broggi
- Department of Medical and Surgical Sciences and Advanced Technologies “G. F. Ingrassia”, Anatomic PathologyUniversity of CataniaCataniaItaly
| | - Arturo Lo Giudice
- Urology Section, Department of SurgeryUniversity of CataniaCataniaItaly
| | - Marina Di Mauro
- Urology Section, Department of SurgeryUniversity of CataniaCataniaItaly
| | - Maria Giovanna Asmundo
- Urology Section, Department of SurgeryUniversity of CataniaCataniaItaly
- Department of UrologyEuropean Institute of Oncology, IRCCSMilanItaly
| | | | - Eliana Piombino
- Department of Experimental OncologyMediterranean Institute of Oncology (IOM)CataniaItaly
| | - Rosario Caltabiano
- Department of Medical and Surgical Sciences and Advanced Technologies “G. F. Ingrassia”, Anatomic PathologyUniversity of CataniaCataniaItaly
| | - Giuseppe Morgia
- Urology Section, Department of SurgeryUniversity of CataniaCataniaItaly
- Department of Experimental OncologyMediterranean Institute of Oncology (IOM)CataniaItaly
| | | |
Collapse
|
6
|
Arun I, Venkatesh S, Ahmed R, Agrawal SK, Leung SCY. Reliability of Ki67 visual scoring app compared to eyeball estimate and digital image analysis and its prognostic significance in hormone receptor-positive breast cancer. APMIS 2021; 129:489-502. [PMID: 34053140 DOI: 10.1111/apm.13156] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 05/03/2021] [Indexed: 12/31/2022]
Abstract
We analysed the reproducibility of Ki67 labelling index (LI) between two scorers using the International Ki67 Working Group (IKWG) global methods on an Android application (APP), correlated the APP and eyeball estimate (EBE) with digital image analysis (DIA) scores and determined the prognostic significance of Ki67LI. Global weighted (GW) and global unweighted (GUW) Ki67 app scores of hormone receptor-positive and HER2 (human epidermal growth factor receptor 2)-negative breast cancer patients were obtained. Reproducibility of Ki67LI between 2 scorers and correlation of APP and EBE scores with DIA scores were performed. The prognostic significance of APP scores and its correlation with other clinico-pathologic variables were evaluated. The intra-class correlation coefficient (ICC) between 2 scorers showed excellent reliability with both GW and GUW methods. ICC between DIA and APP scores was significantly greater than DIA versus EBE. The three categories of APP scores based on median value and cut points of 10%, 18% and 38% were significantly associated with poor DFS. On multivariate analysis, significant association between Ki67LI, tumour size, nodal involvement and DFS was noted. Our study shows that the visual Ki67 scoring app is effective in bringing consistency to KI67LI and APP scores showed significant correlation with DFS.
Collapse
Affiliation(s)
- Indu Arun
- Department of Pathology, Tata Medical Center, Newtown, Kolkata, India
| | - Saranya Venkatesh
- Department of Pathology, Tata Medical Center, Newtown, Kolkata, India
| | - Rosina Ahmed
- Department of Breast Oncosurgery, Tata Medical Center, Newtown, Kolkata, India
| | | | | |
Collapse
|
7
|
Filon M, Gawdzik J, Truong A, Allen G, Huang W, Khemees T, Machhi R, Lewis P, Yang B, Denu J, Jarrard D. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype. Br J Cancer 2021; 125:247-254. [PMID: 33976366 DOI: 10.1038/s41416-021-01398-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 03/06/2021] [Accepted: 04/07/2021] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Histone modifications alter transcriptional gene function and participate in cancer progression. Enhancer-of-Zeste-Homologue-2 (EZH2) and Nuclear-Receptor-Binding-SET-domain2 (NSD2) methylate H3K27 and H3K36, respectively, to regulate transcription. Given the therapeutic interest in these enzymes, we investigated expression and coregulation in hormone-sensitive (HS) and castrate-resistant (CR) prostate cancer (PC). METHODS EZH2 and NSD2 levels were quantified using VECTRA analysis in HS and CRPC tissue microarrays (n = 105 + 66). Expression data from The Cancer Genome Atlas (n = 498), Memorial Sloan Kettering Cancer Center (n = 240), and Stand Up to Cancer/Prostate Cancer Foundation (n = 444) cBioportal datasets were queried, and associations between EZH2 and NSD2 and clinicopathologic variables determined. RESULTS Tumour expression of NSD2, but not EZH2, increased in CRPC (p = 0.05, 0.09). Epithelial nuclei co-expressing NSD2 and EZH2 increased in CRPC compared to HSPC (69 vs 42%, p = 0.02), and in metastatic tissue relative to benign (55 vs 35%, p = 0.02). cBioportal analysis revealed collinear NSD2/EZH2 expression (Spearman = 0.57, 0.58, 0.58, all p < 0.001). NSD2/EZH2 co-expression significantly associates with clinicopathologic characteristics including grade group, stage and seminal vesicle involvement. On univariate and multivariate analysis tumours co-expressing NSD2 and EZH2 conferred increased risk of recurrence (hazard ratio: 2.6, 95% confidence inerval: 1.2-5.4, p = 0.01). Kaplan-Meier analysis revealed reduced progression-free-survival of NSD2 and EZH2 co-expression patients in datasets (p < 0.001, 0.002). CONCLUSIONS Increased EZH2/NSD2 co-expression is overrepresented in CRPC, metastases and associates with shorter disease-free survival in PC patients. Coregulation of these two histone methyltransferases is a biomarker for aggressive PC and licenses them as therapeutic targets.
Collapse
Affiliation(s)
- Mikolaj Filon
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - Joseph Gawdzik
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - Andrew Truong
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - Glenn Allen
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - Wei Huang
- Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Tariq Khemees
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - Rehaan Machhi
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - Peter Lewis
- Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA.,Department of Biomolecular Chemistry, University of Wisconsin, Madison, WI, USA.,Wisconsin Institute for Discovery and the Morgridge Institute for Research, University of Wisconsin, Madison, WI, USA
| | - Bing Yang
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
| | - John Denu
- Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA.,Department of Biomolecular Chemistry, University of Wisconsin, Madison, WI, USA.,Wisconsin Institute for Discovery and the Morgridge Institute for Research, University of Wisconsin, Madison, WI, USA
| | - David Jarrard
- Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. .,Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA. .,Molecular and Environmental Toxicology Program, University of Wisconsin, Madison, WI, USA.
| |
Collapse
|
8
|
Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer. Appl Immunohistochem Mol Morphol 2020; 29:112-117. [DOI: 10.1097/pai.0000000000000835] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2019] [Accepted: 01/12/2020] [Indexed: 11/26/2022]
|
9
|
Lopes N, Bergsland CH, Bjørnslett M, Pellinen T, Svindland A, Nesbakken A, Almeida R, Lothe RA, David L, Bruun J. Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. J Transl Med 2020; 100:120-134. [PMID: 31641225 PMCID: PMC6917572 DOI: 10.1038/s41374-019-0336-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 09/18/2019] [Accepted: 09/18/2019] [Indexed: 01/10/2023] Open
Abstract
Flourescence-based multiplex immunohistochemistry (mIHC) combined with multispectral imaging and digital image analysis (DIA) is a quantitative high-resolution method for determination of protein expression in tissue. We applied this method for five biomarkers (CDX2, SOX2, SOX9, E-cadherin, and β-catenin) using tissue microarrays of a Norwegian unselected series of primary colorectal cancer. The data were compared with previously obtained chromogenic IHC data of the same tissue cores, visually assessed by the Allred method. We found comparable results between the methods, although confirmed that DIA offered improved resolution to differentiate cases with high and low protein expression. However, we experienced inherent challenges with digital image analysis of membrane staining, which was better assessed visually. DIA and mIHC enabled quantitative analysis of biomarker coexpression on the same tissue section at the single-cell level, revealing a strong negative correlation between the differentiation markers CDX2 and SOX2. Both methods confirmed known prognostic associations for CDX2, but DIA improved data visualization and detection of clinicopathological and biological associations. In summary, mIHC combined with DIA is an efficient and reliable method to evaluate protein expression in tissue, here shown to recapitulate and improve detection of known clinicopathological and survival associations for the emerging biomarker CDX2, and is therefore a candidate approach to standardize CDX2 detection in pathology laboratories.
Collapse
Affiliation(s)
- Nair Lopes
- 0000 0004 0389 8485grid.55325.34Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway ,0000 0001 1503 7226grid.5808.5i3S—Institute for Research and Innovation in Health, University of Porto, Porto, Portugal ,0000 0001 1503 7226grid.5808.5IPATIMUP—Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal ,0000 0004 0389 8485grid.55325.34K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway
| | - Christian Holst Bergsland
- 0000 0004 0389 8485grid.55325.34Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway ,0000 0004 0389 8485grid.55325.34K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway ,0000 0004 1936 8921grid.5510.1Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Merete Bjørnslett
- 0000 0004 0389 8485grid.55325.34Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway ,0000 0004 0389 8485grid.55325.34K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway
| | - Teijo Pellinen
- 0000 0004 0389 8485grid.55325.34K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway ,0000 0004 0410 2071grid.7737.4Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Aud Svindland
- 0000 0004 0389 8485grid.55325.34K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway ,0000 0004 1936 8921grid.5510.1Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Arild Nesbakken
- 0000 0004 0389 8485grid.55325.34K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway ,0000 0004 1936 8921grid.5510.1Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway ,0000 0004 0389 8485grid.55325.34Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway
| | - Raquel Almeida
- 0000 0001 1503 7226grid.5808.5i3S—Institute for Research and Innovation in Health, University of Porto, Porto, Portugal ,0000 0001 1503 7226grid.5808.5Faculty of Medicine, University of Porto, Porto, Portugal ,0000 0001 1503 7226grid.5808.5Department of Biology, Faculty of Sciences, University of Porto, Porto, Portugal
| | - Ragnhild A. Lothe
- 0000 0004 0389 8485grid.55325.34Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway ,0000 0004 0389 8485grid.55325.34K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway ,0000 0004 1936 8921grid.5510.1Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Leonor David
- 0000 0001 1503 7226grid.5808.5i3S—Institute for Research and Innovation in Health, University of Porto, Porto, Portugal ,0000 0001 1503 7226grid.5808.5IPATIMUP—Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal ,0000 0001 1503 7226grid.5808.5Faculty of Medicine, University of Porto, Porto, Portugal
| | - Jarle Bruun
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. .,K.G. Jebsen Colorectal Cancer Research Centre, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
| |
Collapse
|
10
|
Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer. Mod Pathol 2020; 33:905-915. [PMID: 31801961 PMCID: PMC7190565 DOI: 10.1038/s41379-019-0418-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 10/21/2019] [Accepted: 10/31/2019] [Indexed: 01/02/2023]
Abstract
The mitotic checkpoint protein BUB3, cyclin B1 (CCNB1) and pituitary tumor-transforming 1 (PTTG1) regulates cell division, and are sparsely studied in prostate cancer. Deregulation of these genes can lead to genomic instability, a characteristic of more aggressive tumors. We aimed to determine the expression levels of BUB3, CCNB1, and PTTG1 as potential prognostic markers of recurrence after radical prostatectomy. Protein levels were determined by immunohistochemistry on three formalin-fixed paraffin-embedded tissue sections from each of the 253 patients treated with radical prostatectomy. Immunohistochemistry scores were obtained by automated image analysis for CCNB1 and PTTG1. Recurrence, defined as locoregional recurrence, distant metastasis or death from prostate cancer, was used as endpoint for survival analysis. Tumors having both positive and negative tumor areas for cytoplasmic BUB3 (30%), CCNB1 (28%), or PTTG1 (35%) were considered heterogeneous. Patients with ≥1 positive tumor area had significantly increased risk of disease recurrence in univariable analysis compared with patients where all tumor areas were negative for cytoplasmic BUB3 (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.41-3.36), CCNB1 (HR = 2.98, 95% CI 1.93-4.61) and PTTG1 (HR = 1.91, 95% CI 1.23-2.97). Combining the scores of cytoplasmic BUB3 and CCNB1 improved risk stratification when integrated with the Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score (difference in concordance index = 0.024, 95% CI 0.001-0.05). In analysis of multiple tumor areas, prognostic value was observed for cytoplasmic BUB3, CCNB1, and PTTG1.
Collapse
|
11
|
Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment. PLoS One 2019; 14:e0212309. [PMID: 30785924 PMCID: PMC6382355 DOI: 10.1371/journal.pone.0212309] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Accepted: 01/31/2019] [Indexed: 12/20/2022] Open
Abstract
The Ki-67 labeling index (LI) is an important prognostic factor in breast carcinoma. The Ki-67 LI is traditionally calculated via unaided microscopic estimation; however, inter-observer and intra-observer variability and low reproducibility are problems with this visual assessment (VA) method. For more accurate assessment and better reproducibility with Ki-67 LI, digital image analysis was introduced recently. We used both VA and automated digital image analysis (ADIA) (Ventana Virtuoso image management software) to estimate Ki-67 LI for 997 cases of breast carcinoma, and compared VA and ADIA results. VA and ADIA were highly correlated (intraclass correlation coefficient 0.982, and Spearman’s correlation coefficient 0.966, p<0.05). We retrospectively analyzed cases with a greater than 5% difference between VA and ADIA results. The cause of these differences was: (1) tumor heterogeneity (98 cases, 56.0%), (2) VA interpretation error (32 cases, 18.3%), (3) misidentification of tumor cells (26 cases, 14.9%), (4) poor immunostaining or slide quality (16 cases, 9.1%), and (5) Estimation of non-tumor cells (3 cases, 1.7%). There were more discrepancies between VA and ADIA results in the group with a VA value of 10–20% compared to groups with <10% and ≥20%. Although ADIA is more accurate than VA, there are some limitations. Therefore, ADIA findings require confirmation by a pathologist.
Collapse
|
12
|
Suer I, Guzel E, Karatas OF, Creighton CJ, Ittmann M, Ozen M. MicroRNAs as prognostic markers in prostate cancer. Prostate 2019; 79:265-271. [PMID: 30345533 DOI: 10.1002/pros.23731] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Accepted: 10/03/2018] [Indexed: 12/21/2022]
Abstract
BACKGROUND Prostate cancer (PCa) is the most commonly diagnosed malignancy in men who are especially over the age of 50 years in the western countries. Currently used therapeutic modalities mostly fail to give positive clinical outcomes and nearly 30% of the PCa patients eventually develop clinical recurrence. Therefore, understanding the underlying mechanisms of PCa progression is of paramount importance to help determining the course of disease. In this study, we aimed at profiling the differentially expressed microRNAs in recurrent PCa samples. METHODS We profiled the microRNA expression of 20 recurrent and 20 non-recurrent PCa patients with microRNA microarray, and validated the differential expression of significantly deregulated microRNAs in 40 recurrent and 39 non-recurrent PCa specimens using quantitative reverse-transcription PCR (qRT-PCR). Data were statistically analyzed using two-sided Student's t-test, Pearson Correlation test, Receiver operating characteristic (ROC) analysis. RESULTS Our results demonstrated that a total of 682 probes were significantly deregulated in recurrent versus non-recurrent PCa specimen comparison. Among those, we confirmed the significant downregulation of miR-424 and upregulation of miR-572 with further qRT-PCR analysis in a larger sample set. Further ROC analysis showed that these microRNAs have enough power to distinguish recurrent specimens from non-recurrent ones on their own. CONCLUSIONS Here, we report that differential expression of miR-424 and miR-572 in recurrent PCa specimens can serve as novel biomarkers for prediction of PCa progression.
Collapse
Affiliation(s)
- Ilknur Suer
- Department of Medical Genetics, Istanbul University, Division of Medical Genetics, Istanbul Faculty of Medicine, Istanbul, Turkey
| | - Esra Guzel
- Department of Molecular Biology and Genetics, Institute of Health Sciences, University of Health Sciences, Istanbul, Turkey
| | - Omer F Karatas
- Molecular Biology and Genetics Department, Erzurum Technical University, Erzurum, Turkey
| | - Chad J Creighton
- Department of Medicine and Dan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, Texas
| | - Michael Ittmann
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas
- Michael E. DeBakey VAMC, Houston, Texas
| | - Mustafa Ozen
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
13
|
Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. Biomark Med 2018; 12:727-736. [PMID: 29902938 DOI: 10.2217/bmm-2017-0322] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM To test if Ki67 expression is prognostic for biochemical recurrence (BCR) after radical prostatectomy (RP). METHODS Ki67 immunohistochemistry was performed on tissue microarrays constructed from specimens obtained from 464 men undergoing RP at the Durham and West LA Veterans Affairs Hospitals. Hazard ratios (HR) for Ki67 expression and time to BCR were estimated using Cox regression. RESULTS Ki67 was associated with more recent surgery year (p < 0.001), positive margins (p = 0.001) and extracapsular extension (p < 0.001). In center-stratified analyses, the adjusted HR for Ki67 expression and BCR approached statistical significance for west LA (HR: 1.54; p = 0.06), but not Durham (HR: 1.10; p = 0.74). CONCLUSION This multi-institutional 'real-world' study provides limited evidence for the prognostic role of Ki67 in predicting outcome after RP.
Collapse
Affiliation(s)
- Joseph J Fantony
- Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
| | - Lauren E Howard
- Urology Section, Durham Veterans Affairs Medical Center, Durham, NC 27705, USA.,Department of Biostatistics and Bioinformatics, Duke School of Medicine, Durham, NC 27705, USA
| | - Ilona Csizmadi
- Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Andrew J Armstrong
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Amy L Lark
- Department of Pathology, Duke University Hospital, Durham, NC 27710, USA.,Department of Pathology, Durham Veterans Affairs Medical Center, Durham, NC 27710, USA
| | - Colette Galet
- Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.,Division of Acute Care Surgery, Department of Surgery, Carver College of Medicine, University of Iowa, IA 52242, USA
| | - William J Aronson
- Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.,Urology Section, Department of Surgery, Greater Los Angeles Veterans Affairs Healthcare System, CA 90073, USA
| | - Stephen J Freedland
- Urology Section, Durham Veterans Affairs Medical Center, Durham, NC 27705, USA.,Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| |
Collapse
|
14
|
Guertin MH, Robitaille K, Pelletier JF, Duchesne T, Julien P, Savard J, Bairati I, Fradet V. Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial. BMC Cancer 2018; 18:64. [PMID: 29321047 PMCID: PMC5763552 DOI: 10.1186/s12885-017-3979-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 12/22/2017] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Prostate cancer is the most commonly diagnosed cancer in north-American men. Few dietary or lifestyle interventions have been tested to prevent prostate cancer progression. Omega-3 fatty acid supplementation represents a promising intervention for prostate cancer patients. The aim of the study is to evaluate the effects of long-chain omega-3 polyunsaturated fatty acids (LCn3), more precisely eicosapentaenoic acid monoacylglyceride (MAG-EPA) supplementation, on prostate cancer proliferation, inflammation mediators and quality of life among men who will undergo radical prostatectomy. METHODS/DESIGN We propose a phase IIb, randomized, double-blind placebo-controlled trial of MAG-EPA supplementation for 130 men who will undergo radical prostatectomy as treatment for a prostate cancer of Gleason score ≥ 7 in an academic cancer center in Quebec City. Participants will be randomized to 6 capsules of 625 mg of fish oil (MAG-EPA) per capsule containing 500 mg of EPA daily or to identically looking capsules of high oleic acid sunflower oil (HOSO) as placebo. The intervention begins 4 to 10 weeks prior to radical prostatectomy (baseline) and continues for one year after surgery. The primary endpoint is the proliferative index (Ki-67) measured in prostate cancer cells at radical prostatectomy. A secondary endpoint includes prostate tissue levels of inflammatory mediators (cytokines and proteins) at time of radical prostatectomy. Changes in blood levels of inflammatory mediators, relative to baseline levels, at time of radical prostatectomy and 12 months after radical prostatectomy will also be evaluated. Secondary endpoints also include important aspects of psychosocial functioning and quality of life such as depression, anxiety, sleep disturbances, fatigue, cognitive complaints and prostate cancer-specific quality of life domains. The changes in these outcomes, relative to baseline levels, will be evaluated at 3, 6, 9 and 12 months after radical prostatectomy. DISCUSSION The results from this trial will provide crucial information to clarify the role of omega-3 supplementation on prostate cancer proliferation, inflammation and quality of life. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02333435. Registered on December 17, 2014. Last updated September 6, 2016.
Collapse
Affiliation(s)
- Marie-Hélène Guertin
- Oncology Unit, Centre de recherche du CHU de Québec – Université Laval - L’Hôtel-Dieu de Québec, 6 rue McMahon, Québec, QC Canada
| | - Karine Robitaille
- Oncology Unit, Centre de recherche du CHU de Québec – Université Laval - L’Hôtel-Dieu de Québec, 6 rue McMahon, Québec, QC Canada
| | - Jean-François Pelletier
- Oncology Unit, Centre de recherche du CHU de Québec – Université Laval - L’Hôtel-Dieu de Québec, 6 rue McMahon, Québec, QC Canada
| | - Thierry Duchesne
- Mathematics and Statistics Department, Université Laval, 1045 avenue de la médecine, Bureau, Québec, QC 1056 Canada
| | - Pierre Julien
- Endocrinology and Nephrology Unit, Centre de recherche du CHU de Québec – Université Laval - CHUL, 2705, boulevard Laurier, Québec, QC Canada
| | - Josée Savard
- Oncology Unit, Centre de recherche du CHU de Québec – Université Laval - L’Hôtel-Dieu de Québec, 6 rue McMahon, Québec, QC Canada
| | - Isabelle Bairati
- Oncology Unit, Centre de recherche du CHU de Québec – Université Laval - L’Hôtel-Dieu de Québec, 6 rue McMahon, Québec, QC Canada
| | - Vincent Fradet
- Oncology Unit, Centre de recherche du CHU de Québec – Université Laval - L’Hôtel-Dieu de Québec, 6 rue McMahon, Québec, QC Canada
| |
Collapse
|
15
|
Fu L, Hwang M, Adeniran AJ, Humphrey PA. Proliferation index of different Gleason pattern 4 histomorphologies and associated pattern 3 adenocarcinoma of the prostate. Hum Pathol 2017; 70:1-5. [DOI: 10.1016/j.humpath.2017.06.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Revised: 06/02/2017] [Accepted: 06/14/2017] [Indexed: 01/31/2023]
|
16
|
Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PLoS One 2017; 12:e0186852. [PMID: 29141018 PMCID: PMC5687762 DOI: 10.1371/journal.pone.0186852] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Accepted: 10/09/2017] [Indexed: 12/01/2022] Open
Abstract
The tumor proliferation index marker Ki-67 is strongly associated with tumor cell proliferation, growth and progression, and is widely used in routine clinicopathological investigation. Prostate cancer is a complex multifaceted and biologically heterogeneous disease, and overtreatment of localized, low volume indolent tumors, is evident. Here, we aimed to assess Ki-67 expression and related outcomes of 535 patients treated with radical prostatectomy. The percentage of tumor epithelial cells expressing Ki-67 was determined by immunohistochemical assay, both digital image analysis and visual scoring by light microscope were used for quantification. The association of Ki-67 and prostate cancer was evaluated, as well as its prognostic value. There was a positive correlation between high expression of Ki-67 and Gleason score > 7 (p < 0.001) as well as tumor size (≥ 20 mm, p = 0.03). In univariate analyses, a high expression of Ki-67 in tumor epithelium was significantly associated with biochemical failure (BF) (digital scoring, p = 0.014) and (visual scoring, p = 0.004). In the multivariate analyses, a high level of Ki-67 was an independent poor prognostic factor for biochemical failure-free survival (BFFS) (Visual scoring, Ki67, p = 0.012, HR:1.50, CI95% 1.10–2.06). In conclusion, high Ki-67 expression is an independent negative prognostic marker for biochemical failure. Our findings support the role of Ki-67 as a significant, poor prognostic factor for in prostate cancer outcome.
Collapse
|
17
|
Diagnostic utility of Ki-67 immunohistochemistry in small endoscopic biopsies of the ureter and renal pelvis. Pathol Res Pract 2017; 213:737-741. [DOI: 10.1016/j.prp.2017.04.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Revised: 03/15/2017] [Accepted: 04/12/2017] [Indexed: 11/19/2022]
|
18
|
Zhang C, Lu J, Zhang QW, Zhao W, Guo JH, Liu SL, Wu YL, Jiang B, Gao FH. USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells. Int J Biochem Cell Biol 2016; 79:209-221. [PMID: 27590858 DOI: 10.1016/j.biocel.2016.08.025] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Revised: 08/07/2016] [Accepted: 08/29/2016] [Indexed: 10/21/2022]
Abstract
The Ki-67 antigen (Ki-67) is the most reliable immunohistochemical marker for evaluation of cell proliferation in non-small cell lung cancer. However, the mechanisms underlying the regulation of protein levels of Ki-67 in non-small cell lung cancer have remained elusive. In this study, we found that Ki-67 and ubiquitin-specific processing protease 7 (USP7) protein were highly expressed in the nucleus of non-small cell lung cancer cells. Furthermore, statistical analysis uncovered the existence of a strong correlation between Ki-67 and USP7 levels. We could also show that the protein levels of Ki-67 in non-small cell lung cancer cells significantly decreased after treatment with P22077, a selective chemical inhibitor of USP7, while the Ki-67 mRNA levels were unperturbed. Similar results were obtained by knocking down USP7 using short hairpin RNA (shRNA) in lung cancer cells. Interestingly, we noticed that ubiquitination levels of Ki-67 increased dramatically in USP7-silenced cells. The tests in vitro and vivo showed a significant delay in tumor cell growth upon knockdown of USP7. Additionally, drug sensitivity tests indicated that USP7-silenced A549 cells had enhanced sensitivity to paclitaxel and docetaxel, while there was no significant change in sensitivity toward carboplatin and cisplatin. Taken together, these data strongly suggest that the overexpression of USP7 might promote cell proliferation by deubiquitinating Ki-67 protein, thereby maintaining its high levels in the non-small cell lung cancer. Our study also hints potential for the development of deubiquitinase-based therapies, especially those targeting USP7 to improve the condition of patients diagnosed with non-small cell lung cancer.
Collapse
Affiliation(s)
- Chao Zhang
- Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Rd, Shanghai 200011, China
| | - Jing Lu
- Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Rd, Shanghai 200011, China
| | - Quan-Wu Zhang
- Department of Pathology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China
| | - Wei Zhao
- Department of Pathology, The First People's Hospital of Changzhou (The Third Affiliated Hospital of Soochow University), Changzhou 213003, China
| | - Jia-Hui Guo
- Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Rd, Shanghai 200011, China
| | - Shan-Ling Liu
- Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Rd, Shanghai 200011, China
| | - Ying-Li Wu
- Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Bin Jiang
- Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Rd, Shanghai 200011, China.
| | - Feng-Hou Gao
- Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Rd, Shanghai 200011, China.
| |
Collapse
|
19
|
Rizzardi AE, Zhang X, Vogel RI, Kolb S, Geybels MS, Leung YK, Henriksen JC, Ho SM, Kwak J, Stanford JL, Schmechel SC. Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer. Diagn Pathol 2016; 11:63. [PMID: 27401406 PMCID: PMC4940862 DOI: 10.1186/s13000-016-0511-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 07/01/2016] [Indexed: 12/02/2022] Open
Abstract
Background Digital image analysis offers advantages over traditional pathologist visual scoring of immunohistochemistry, although few studies examining the correlation and reproducibility of these methods have been performed in prostate cancer. We evaluated the correlation between digital image analysis (continuous variable data) and pathologist visual scoring (quasi-continuous variable data), reproducibility of each method, and association of digital image analysis methods with outcomes using prostate cancer tissue microarrays (TMAs) stained for estrogen receptor-β2 (ERβ2). Methods Prostate cancer TMAs were digitized and evaluated by pathologist visual scoring versus digital image analysis for ERβ2 staining within tumor epithelium. Two independent analysis runs were performed to evaluate reproducibility. Image analysis data were evaluated for associations with recurrence-free survival and disease specific survival following radical prostatectomy. Results We observed weak/moderate Spearman correlation between digital image analysis and pathologist visual scores of tumor nuclei (Analysis Run A: 0.42, Analysis Run B: 0.41), and moderate/strong correlation between digital image analysis and pathologist visual scores of tumor cytoplasm (Analysis Run A: 0.70, Analysis Run B: 0.69). For the reproducibility analysis, there was high Spearman correlation between pathologist visual scores generated for individual TMA spots across Analysis Runs A and B (Nuclei: 0.84, Cytoplasm: 0.83), and very high correlation between digital image analysis for individual TMA spots across Analysis Runs A and B (Nuclei: 0.99, Cytoplasm: 0.99). Further, ERβ2 staining was significantly associated with increased risk of prostate cancer-specific mortality (PCSM) when quantified by cytoplasmic digital image analysis (HR 2.16, 95 % CI 1.02–4.57, p = 0.045), nuclear image analysis (HR 2.67, 95 % CI 1.20–5.96, p = 0.016), and total malignant epithelial area analysis (HR 5.10, 95 % CI 1.70–15.34, p = 0.004). After adjusting for clinicopathologic factors, only total malignant epithelial area ERβ2 staining was significantly associated with PCSM (HR 4.08, 95 % CI 1.37–12.15, p = 0.012). Conclusions Digital methods of immunohistochemical quantification are more reproducible than pathologist visual scoring in prostate cancer, suggesting that digital methods are preferable and especially warranted for studies involving large sample sizes. Electronic supplementary material The online version of this article (doi:10.1186/s13000-016-0511-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Anthony E Rizzardi
- Department of Pathology, University of Washington, 908 Jefferson Street, Room 2NJB244, Seattle, WA, 98104, USA.,Department of Pathology, University of Washington, 300 Ninth Ave, Research & Training Building, Room 421, Seattle, WA, 98104, USA
| | - Xiaotun Zhang
- Department of Urology, University of Washington, Seattle, WA, USA
| | - Rachel Isaksson Vogel
- Biostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
| | - Suzanne Kolb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Milan S Geybels
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Yuet-Kin Leung
- Divison of Environmental Genetics and Molecular Toxicology, University of Cincinnati, Cincinnati, OH, USA.,Center for Environmental Genetics, Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, OH, USA.,Department of Environmental Health, Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, OH, USA
| | - Jonathan C Henriksen
- Department of Pathology, University of Washington, 908 Jefferson Street, Room 2NJB244, Seattle, WA, 98104, USA
| | - Shuk-Mei Ho
- Divison of Environmental Genetics and Molecular Toxicology, University of Cincinnati, Cincinnati, OH, USA.,Center for Environmental Genetics, Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, OH, USA.,Department of Environmental Health, Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, OH, USA
| | - Julianna Kwak
- Department of Pathology, University of Washington, 908 Jefferson Street, Room 2NJB244, Seattle, WA, 98104, USA
| | - Janet L Stanford
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA
| | - Stephen C Schmechel
- Department of Pathology, University of Washington, 908 Jefferson Street, Room 2NJB244, Seattle, WA, 98104, USA.
| |
Collapse
|